Top Abstract Purchase Related
Home
>
Node
>
Subnode

Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin

Soueidan, S.A.; Dalakas, M.C.

Neurology 43(5): 876-879

1993

ISSN/ISBN: 0028-3878
PMID: 8492940
Document Number: 412962
We report the treatment of four patients with inclusion-body myositis (IBM) and severe slowly progressive weakness using high-dose intravenous immunoglobulin (IVIg). After two monthly infusions, the strength of the proximal and less atrophic muscle groups improved or normalized in three of the four patients. The improvement lasted from 2 to 4 months. Intravenous immunoglobulin is the first treatment modality to improve the strength of some muscles in patients with this disabling inflammatory myopathy. In view of the high cost of IVIg, the unexpected but encouraging results from this pilot study warrant a controlled trial.

Document emailed within 1 workday
Secure & encrypted payments

Salvarani, C.; Boiardi, L.; Maldini, M.C.; Mancini, R.; Rinaldi, M.; Macchioni, P.; Portioli, I. 1993: High dose immunoglobulin therapy in a case of inclusion body myositis: clinical and immunologic aspects Journal of Rheumatology 20(8): 1455-1456
Dobloug, C.; Walle-Hansen, R.; Gran, J.Tore.; Molberg, Øyvind. 2012: Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients Clinical and Experimental Rheumatology 30(6): 838-842
Taneichi, H.; Miyawaki, T. 2011: High-dose intravenous immunoglobulin treatment Nihon Rinsho. Japanese Journal of Clinical Medicine 69(3): 515-519
Winder, A.; Molad, Y.; Ostfeld, I.; Kenet, G.; Pinkhas, J.; Sidi, Y. 1993: Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases Journal of Rheumatology 20(3): 495-498
Lehn, P.; Quessar, A.; Devergie, A.; Esperou-Bourdeau, H.; Traineau, R.; Trédaniel, J.; Benbunan, M.; Bussel, A.; Jolivet, I.; Mazeron, M.C. 1990: Treatment of severe cytomegalovirus infection with ganciclovir and high-dose intravenous immunoglobulin in patients with allogeneic bone marrow transplants. a pilot study Nouvelle Revue Francaise d'Hematologie 32(1): 17-20
Gayathri, N.; Anisya-Vasanth; Veerendra Kumar, M.; Das, S.; Santosh, V.; Yasha, T.C.; Ramamohan, Y.; Taly, A.B.; Gourie-Devi, M.; Shankar, S.K. 2000: Inclusion body myositis (IBM) Clinical Neuropathology 19(1): 13-20
Mendell, J.R.; Sahenk, Z. 1992: Inclusion body myositis Neurology 42(11): 2231-2232
Badrising, U.A.; Maat-Schieman, M.L.; van Duinen, S.G.; van Dijk, J.G.; Verschuuren, J.J.; Wintzen, A.R. 1998: 'Inclusion body'-myositis Nederlands Tijdschrift Voor Geneeskunde 142(11): 553-557
Korsak, J.; Zaleska, B.; Orłowska, E.; Kotowicz, J. 2005: Use of high dose intravenous immunoglobulin in neurologic disease Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 19(109): 98-101
Quartuccio, L.; De Marchi, G.; Scott, C.A.; Ferraccioli, G.; Beltrami, C.A.; De Vita, S. 2007: Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features Clinical and Experimental Rheumatology 25(2): 246-251
Albrecht, S.; Bilbao, J.M. 1993: Ubiquitin expression in inclusion body myositis. An immunohistochemical study Archives of Pathology and Laboratory Medicine 117(8): 789-793
Alexandrescu, D.T.; Bhagwati, N.S.; Fomberstein, B.; Wolfe, D.E.; Feliz, A.; Wiernik, P.H. 2005: Steroid-responsive inclusion body myositis associated with endometrial cancer Clinical and Experimental Rheumatology 23(1): 93-96
Bertorini, T.E. 1998: Inflammatory myopathies [polymyositis, dermatomyositis, inclusion body myositis Comprehensive Therapy 24(10): 494-502
McCoy, A.L.; Bubb, M.R.; Plotz, P.H.; Davis, J.C. 1999: Inclusion body myositis long after dermatomyositis: a report of two cases Clinical and Experimental Rheumatology 17(2): 235-239
Hoogendijk, J.E.; Bijlsma, J.W.J.; van Engelen, B.G.M.; Lindeman, E.; van Royen-Kerkhof, A.; de Rie, M.A.; de Visser, M.; Jennekens, F.G.I. 2005: The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis' Nederlands Tijdschrift Voor Geneeskunde 149(38): 2104-2111
Lindberg, C.; Oldfors, A. 1995: Inclusion body myositis. An underdiagnosed disease with creeping muscular fatigue Lakartidningen 92(10): 973-976
Albayda, J.; Christopher-Stine, L.; Bingham Iii, C.O.; Paik, J.J.; Tiniakou, E.; Billings, S.; Uy, O.M.; Burlina, P. 2018: Pattern of muscle involvement in inclusion body myositis: a sonographic study Clinical and Experimental Rheumatology 36(6): 996-1002
Deshmukh, S.; White, G.; Katifi, H.A.; Malik, N. 2008: Inclusion body myositis a clinical review with illustrative case report Acute Medicine 7(2): 73-76
Maksymowych, W.P.; Aviña-Zubieta, A.; Luong, M.; Russell, A.S. 1996: High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy Clinical and Experimental Rheumatology 14(6): 657-660
Wilson, F.C.; Ytterberg, S.R.; St Sauver, J.L.; Reed, A.M. 2008: Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota Journal of Rheumatology 35(3): 445-447